Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science (R21)

The summary for the Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science (R21): Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing technically innovative feasibility studies focused on early stage development of cancer-relevant technologies that address the issues related to pre-analytical variations in the collection, processing, handling, and storage of biospecimens or its derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or their derived samples for downstream molecular analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to have a potential to accelerate and/or enhance the research in cancer biology, prevention, diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen and/or sample quality. All projects must include quantitative milestones (i.e. technical metrics that determine whether the specific aims have been accomplished). This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Mechanism of Support. This FOA will utilize the NIH Exploratory/Developmental (R21) grant mechanism, and runs parallel with a FOA of identical scientific scope, RFA-CA-10-002, that solicits applications under the NIH R33 grant mechanism. Funds Available and Anticipated Number of Awards. The NCI intends to commit a total of approximately $1,500,000 to this FOA in fiscal year 2010 to fund up to seven applications in response to this FOA. Budget and Project Period. The total project period for an application submitted in response to this FOA may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year.